Epigenomics AG has announced plans to work with the Munich Technical University and clinicians in Bavaria to test the viability of a blood-based biomarker for detecting precancerous lesions. The German government is helping to fund the project.
Epigenomics AG has announced plans to work with the Munich Technical University and clinicians in Bavaria to test the viability of a blood-based biomarker for detecting precancerous lesions. The German government is helping to fund the project.